BURLINGAME, Calif., Oct. 21 /PRNewswire/ -- Sensorin, which is developing and commercializing a novel self-calibrating pH measurement platform for bioprocess applications, today announced the closing of its second round of equity funding. Use of proceeds from the financing includes product development, beta testing and launch of Sensorin's proprietary pH sensing system. Terms of the financing were not disclosed.
"Sensorin is funded by a distinguished group of individual investors with first-hand biopharmaceutical experience who are aware of the problems associated with current pH probes and who recognize the large commercial opportunity for better in-line pH measurement," said Carolyn Kahn, Ph.D., Sensorin president and CEO. "Sensorin's system represents a compelling solution for bioprocessing, including fixed and disposable fermentation systems and downstream processing."
"Improved pH control has the potential to significantly increase biopharmaceutical yields," commented Frank Jackson, former Vice President of Vacaville Product Operations for Genentech, Inc., and a Sensorin investor and advisor. "Although internally referenced approaches to measuring pH have been explored in academia, Sensorin has developed the only platform capable of in-line pH measurement without calibration, without drift and without fouling during extended periods of cell culture."
Sensorin obtained seed financing and began operations in the third quarter of 2007. The company rapidly demonstrated proof-of-concept for its proprietary technology platform, achieving this goal by the end of 2007. Sensorin is currently developing a beta version of its system for customer testing, with a prospective commercial launch in 2009.
Sensorin intends to address biologics manufacturing with its first- generation pH measurement system. The technology can be extended to other industrial pH applications, including waste-water processing and oil, gas and biofuels production.
About the Sensorin pH Measurement System
The Sensorin(TM) pH measurement system combines reusable electronic components with Sensorin's innovative solid-state pH sensor embedded in a disposable probe. Using a proprietary, internally referenced approach that is self-calibrating and drift free and does not foul in cell culture, the Sensorin system enables in-line, operator-independent pH monitoring. Sensorin's pH probes are highly accurate, precise, robust and easy to use and are designed to integrate with existing pH control equipment for bioprocessing.
Sensorin's Board of Directors
In addition to Dr. Kahn, Sensorin's board members include chairman Alan M. Mendelson, general partner of Axiom Ventures; Steve Allen, Ph.D., Managing Director of LGC Forensics and former executive of Perkin-Elmer Instruments and Mettler Toledo; George Milne, Jr., Ph.D., Executive Chairman of Rib-X, Venture Partner of Radius Ventures and former EVP of Global Research and Development of Pfizer; and Linda Rubinstein, principal of RDJ Advisors and former CFO of Solexa.
Sensorin is developing and commercializing a novel, proprietary and
versatile sensing technology platform. The company is initially focusing on
pH measurement in high-value manufacturing, where an internally referenced,
self-calibrating system without drift is advantageous. The Sensorin system
is solid state, reliable, accurate and robust for deployment in process
applications. The company anticipates launching its pH sensing system for
biologics manufacturing in 2009. For further information, please visit
For further information, contact:
EVC Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved